- Home
- ASRV vs SPRO Comparison
ASRV vs SPRO Comparison
Compare ASRV & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRV
- SPRO
- Stock Information
- Founded
- ASRV 1983
- SPRO 2013
- Country
- ASRV United States
- SPRO United States
- Employees
- ASRV N/A
- SPRO N/A
- Industry
- ASRV Major Banks
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- ASRV Finance
- SPRO Health Care
- Exchange
- ASRV Nasdaq
- SPRO Nasdaq
- Market Cap
- ASRV 40.3M
- SPRO 45.7M
- IPO Year
- ASRV N/A
- SPRO 2017
- Fundamental
- Price
- ASRV $2.43
- SPRO $0.72
- Analyst Decision
- ASRV
- SPRO Buy
- Analyst Count
- ASRV 0
- SPRO 4
- Target Price
- ASRV N/A
- SPRO $5.00
- AVG Volume (30 Days)
- ASRV 19.4K
- SPRO 118.7K
- Earning Date
- ASRV 04-15-2025
- SPRO 03-27-2025
- Dividend Yield
- ASRV 4.86%
- SPRO N/A
- EPS Growth
- ASRV N/A
- SPRO N/A
- EPS
- ASRV 0.21
- SPRO N/A
- Revenue
- ASRV $53,139,000.00
- SPRO $47,977,000.00
- Revenue This Year
- ASRV N/A
- SPRO N/A
- Revenue Next Year
- ASRV N/A
- SPRO N/A
- P/E Ratio
- ASRV $11.62
- SPRO N/A
- Revenue Growth
- ASRV 18.14
- SPRO N/A
- 52 Week Low
- ASRV $2.20
- SPRO $0.70
- 52 Week High
- ASRV $3.06
- SPRO $1.81
- Technical
- Relative Strength Index (RSI)
- ASRV 45.54
- SPRO 38.19
- Support Level
- ASRV $2.33
- SPRO $0.75
- Resistance Level
- ASRV $2.52
- SPRO $0.80
- Average True Range (ATR)
- ASRV 0.11
- SPRO 0.05
- MACD
- ASRV 0.01
- SPRO 0.00
- Stochastic Oscillator
- ASRV 45.45
- SPRO 9.09
About ASRV AmeriServ Financial Inc.
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.